RefleXion PET/CT Imaging Performance in Patients With Various Malignancies

Status Recruiting

Clinical Trial Summary

This clinical trial examines RefleXion Medical Radiotherapy System (RMRS) imaging to the standard of care (SOC) fludeoxyglucose F-18 ([18F]-FDG)- positron emission tomography (PET)-computed tomography (CT) imaging in patients with various cancers (malignancies). PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, [18F]-FDG. Because some cancers take up [18F]-FDG, cancer cells can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body. The RefleXion system is designed to facilitate delivery of biology-guided radiotherapy (BgRT). The RMRS uses PET emissions to guide radiotherapy delivery in real-time and has been studied for use with FDG (which is an agent used in standard PET-CT scans that targets glucose). Information gathered from this study may help researchers to improve PET-CT imaging on the RefleXion system. This information will be used in the future to improve planning and delivery of radiotherapy that will target (in real time) the signal released from the [18F]-FDG-PET-CT tracer. Comparing the imaging from the standard of care [18F]-FDG-PET-CT with the [18F]-FDG imaging from RMRS may help improve the quality of the imaging captured and determine if imaging can be done on the RMRS at the same time as planning for radiation therapy, which would reduce the number of scans needed to plan for radiation for cancer.

Clinical Trial Description

PRIMARY OBJECTIVE: I. To assess imaging performance of the [18F]-FDG PET-CT subsystem on the X1 RMRS to detect lesions (primary and metastatic) in patients with various types of malignancies. SECONDARY OBJECTIVE: I. To determine the feasibility of generating a BgRT plan using X1 RMRS-acquired [18F]-FDG PET data derived from the imaging-only session at the studied dose level. OUTLINE: Patients receive [18F]-FDG injection and undergo SOC [18F]-FDG PET-CT on study. Patients with at least one PET avid lesion then undergo X1 RMRS PET-CT imaging-only session on study. ;

Study Design

Related Conditions & MeSH terms

Hematopoietic and Lymphoid System Neoplasm
Malignant Solid Neoplasm
Neoplasms

Clinical Trial Details

NCT number	NCT05844306
Study type	Interventional
Source	City of Hope Medical Center
Contact
Status	Recruiting
Phase	N/A
Start date	March 15, 2023
Completion date	February 28, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06030427` - Virtual Mindfulness and Weight Management to Mitigate Risk of Relapse and Improve Wellbeing in Cancer Survivors	N/A
Completed	`NCT04337203` - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship	N/A
Recruiting	`NCT05660421` - Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors	Phase 2
Suspended	`NCT04060849` - Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY	Phase 1
Recruiting	`NCT06192875` - A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)
Completed	`NCT04122118` - Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor	N/A
Active, not recruiting	`NCT04940299` - Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma	Phase 2
Active, not recruiting	`NCT03168737` - 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients	Phase 1
Active, not recruiting	`NCT06062901` - An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors	N/A
Active, not recruiting	`NCT02444741` - Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer	Phase 1/Phase 2
Terminated	`NCT04081298` - eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors	N/A
Active, not recruiting	`NCT04555837` - Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer	Phase 1/Phase 2
Completed	`NCT04983901` - PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN	Phase 2
Active, not recruiting	`NCT04602026` - The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer	N/A
Recruiting	`NCT04871542` - Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Active, not recruiting	`NCT04592250` - Financial Toxicity in Cancer Patients
Recruiting	`NCT05112614` - Role of Gut Microbiome in Cancer Therapy
Active, not recruiting	`NCT04296305` - Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain	Phase 4
Recruiting	`NCT05873608` - Communication Issues in Patient and Provider Discussions of Immunotherapy	N/A
Recruiting	`NCT02464696` - Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure	N/A